Mysimba 8 mg/90 mg Tablets – Naltrexone & Bupropion

Mysimba 8 mg/90 mg prolonged-release tablets contain two active ingredients: naltrexone hydrochloride and bupropion hydrochloride. Each tablet contains 8 mg of naltrexone hydrochloride, equivalent to 7.2 mg of naltrexone, and 90 mg of bupropion hydrochloride, equivalent to 78 mg of bupropion.

Mysimba belongs to the medicines used for weight management. Doctors prescribe it alongside a reduced-calorie diet and increased physical activity for eligible adults who meet specific BMI and health criteria. The European Medicines Agency lists Mysimba for adults with obesity or adults who are overweight and have certain weight-related health conditions.

Mysimba combines naltrexone and bupropion. These active ingredients affect areas of the brain involved in food intake, energy balance and the rewarding effects associated with eating. The exact mechanism that produces the weight-management effect remains complex.

Mysimba uses a prolonged-release tablet formulation. Doctors normally introduce treatment gradually over the first four weeks before reaching the recommended maintenance schedule. Healthcare professionals should assess a patient’s response and tolerability throughout treatment.

The current product information includes important precautions and contraindications. Mysimba can affect blood pressure and heart rate and can interact with other medicines, including opioid-containing medicines. Patients should review the official prescribing information and discuss their complete medication history with their doctor or pharmacist before treatment.

European regulators have also introduced additional recommendations concerning the long-term cardiovascular safety of Mysimba, including an annual reassessment for patients who continue treatment. Healthcare professionals should follow the latest regulatory guidance when prescribing Mysimba.

Mysimba is a prescription medicine. Patients should use it only under appropriate medical supervision and follow the instructions provided with their prescription.

This product description provides general educational information and does not replace the official patient leaflet, prescribing information or advice from a qualified healthcare professional.

Official Mysimba Information

For complete prescribing information, contraindications, warnings, interactions and dosing information, review the official Mysimba Summary of Product Characteristics.

Patients can also read the official Mysimba Patient Information Leaflet for information about taking the medicine and possible side effects.

You can also review the European Medicines Agency information on Mysimba for regulatory and